DrugPatentWatch Database Preview
OFEV Drug Profile
When do Ofev patents expire, and when can generic versions of Ofev launch?
Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this drug.
This drug has one hundred and seventy-two patent family members in forty-six countries.
The generic ingredient in OFEV is nintedanib esylate. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nintedanib esylate profile page.
Summary for OFEV
| International Patents: | 172 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 111 |
| Patent Applications: | 77 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for OFEV |
| DailyMed Link: | OFEV at DailyMed |
Generic Entry Opportunity Date for OFEV
Generic Entry Date for OFEV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for OFEV
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors |
Synonyms for OFEV
| (Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate |
| (Z)-Methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)-phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate |
| (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate |
| 1160294-26-7 |
| 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone |
| 656247-17-5 |
| 928326-83-4 |
| A10955 |
| AB0035905 |
| AB1006397 |
| ABP000857 |
| ACN-030189 |
| AK170374 |
| AKOS005145820 |
| AN-5281 |
| AOB5742 |
| BC297819 |
| BCP9000405 |
| BDBM50026612 |
| BIBF 1120 |
| BIBF 1120|||Intedanib|||Vargatef |
| BIBF-1120 |
| BIBF1120 |
| Bibf1120 - Vargatef |
| BIBF1120,BIBF-1120,Vargatef/ |
| BIBF1120,Vargatef |
| BRD-K49075727-001-01-0 |
| C31H33N5O4 |
| cc-88 |
| CHEBI:85164 |
| CS-0104 |
| D09HNV |
| D0J1OJ |
| D10481 |
| DB09079 |
| EX-A341 |
| G6HRD2P839 |
| GTPL5936 |
| HSDB 8339 |
| HY-50904 |
| Intedanib |
| J-502642 |
| KB-75518 |
| KS-1434 |
| Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1h-indole-6-carboxylate |
| methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-1H-indole-6-carboxylate |
| methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate |
| methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate |
| methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenyl-methylene]-2-oxo-indoline-6-carboxylate |
| Methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate |
| Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate |
| methyl (Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate |
| MFCD11974012 |
| MLS006010165 |
| MolPort-009-679-380 |
| nibtedanib |
| Nintedanib |
| Nintedanib (BIBF 1120) |
| Nintedanib (BIBF-1120) |
| Nintedanib (USAN/INN) |
| Nintedanib [USAN:INN] |
| PubChem20543 |
| QCR-43 |
| RL05845 |
| RS0107 |
| s1010 |
| SC-85732 |
| SCHEMBL431006 |
| SCHEMBL431007 |
| SMR004701273 |
| SYN1091 |
| Tube722 |
| UNII-G6HRD2P839 |
| Vargatef |
| Vargatef (TN) |
| Vargatef, BIBF 1120 |
| X7367 |
| XIN |
| XZXHXSATPCNXJR-ZIADKAODSA-N |
| Y0352 |
| ZINC100014909 |
US Patents and Regulatory Information for OFEV
International Patents for OFEV
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Mexico | 338001 | ➤ Try a Free Trial |
| Portugal | 1527047 | ➤ Try a Free Trial |
| Egypt | 25931 | ➤ Try a Free Trial |
| South Korea | 20050042139 | ➤ Try a Free Trial |
| Japan | 2007302697 | ➤ Try a Free Trial |
| Czech Republic | 20021410 | ➤ Try a Free Trial |
| Denmark | 1224170 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for OFEV
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 15/017 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: VARGATEF-NINTEDANIB, THE TAUTOMERS AND THE PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121 |
| 2015015 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121 |
| 2015015,C1224170 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121 |
| 00725 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121 |
| C0024 | France | ➤ Try a Free Trial | PRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET SES SELS,EN PARTICULIER LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/954 20141125 |
| 0725 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125 |
| 90015-2 | Sweden | ➤ Try a Free Trial | PRODUCT NAME: NINTEDANIB, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE; REG. NO/DATE: EU/1/14/954 20141121 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
